At the 56th annual European Association for the Study of Diabetes (EASD) 2020 meeting, positive results have been discussed for…
Since early March, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the Covid-19 pandemic. Many companies have delayed the initiation of…
A total of 29 million confirmed cases of Covid-19 have been reported worldwide, with the number of deaths approaching one million: 925,000 to be exact, as of 15 September 2020.…
by William Newton in Texas Alkermes’ ALKS-3831 for schizophrenia and bipolar disorder has evoked mixed expert forecasts for how a Food and Drug Administration (FDA) Advisory Committee (AdCom) meeting on…
by Ayisha Sharma in London. Subcutaneous (SC) formulations of Apellis Pharmaceuticals’ pegcetacoplan and Alexion Pharmaceuticals’ Ultomiris (ravulizumab-cwvz) are unlikely to have widespread uptake in first-line paroxysmal nocturnal haemoglobinuria (PNH) despite…
by Ayisha Sharma in London. Santhera Pharmaceuticals’ vamorolone for Duchenne muscular dystrophy (DMD) has experts cautious on how an uncontrolled diet in the Phase IIb VISION-DMD trial will impact the potential…
Over the last three months, the number of clinical trials being disrupted due to COVID-19 has been decreasing, despite a rise in the number of COVID-19 cases. This suggests that…